Pinned Tweet
Most earnings coverage tells you what CEOs said.
We show what changed.
August: CVS stressed the value of integration.
November: CVS announced plans to split in two.
Call Shifts compares earnings calls: shifts, promises and unanswered questions.
Follow for the receipts.
2
94
In August, XPeng (NYSE: XPEV) said IRON would reach scaled production by year-end and launch for external customers in 2027. On Nov. 16 CEO He Xiaopeng set the dates: mass production from Jan. 1, store trials in Q1, external launch in Q2.
• Deliveries begin in Q2, he said in Q&A
Analysis, not advice. I don't hold XPeng (NYSE: XPEV).
1
19
In July, ABB India's CFO would not size the return to mid-teens EBITDA margin. On Nov. 16 T.K. Sridhar said margins should be in a 13%-15% range as the backlog is executed.
• He tied it to material costs, commodity prices and geopolitics
Analysis, not advice. I don't hold ABB India (NSE: ABB).
34
Before the call I listed 3 promises $NVDA made. It kept 3.
First report under interim CEO Colette Kress.
• Q3 revenue: $115.8B vs a $108B ± 2% guide
• Vera Rubin: nearly $20B, close to the 20% of Data Center promised
• Fiscal 2028 growth: now about 75%, up from 70%
• Q4 guide: $130B ± 3%
Analysis, not advice. I don't hold $NVDA.
52
In August, Ashok Leyland's CEO said Q2 would be the peak of input-cost pressure and Q3 should soften. On Nov. 16 Shenu Agarwal said Q3 would also be a bad quarter for inflation, with steel and natural rubber already pushing up costs.
• Q2 EBITDA margin held at 10.1% on revenue up 39%
Analysis, not advice. I don't hold Ashok Leyland (NSE: ASHOKLEY).
100
In August, Tyson's then-CEO said 2027 would bring growth in volume and profitability. On Nov. 16 CFO Curt Calaway guided FY2027 sales down 3.5%-5.5% on a 52-week basis, mainly on lower beef volume.
• Chicken profit is seen at $1.3B-$1.6B, below FY2026
Analysis, not advice. I don't hold Tyson Foods (NYSE: TSN).
17
In August, Aramark (NYSE: ARMK) put Nexus at $400M-$500M of annualized revenue from three sites, ramping over FY27 into FY28. On Nov. 16 it said it expects about $500M of Nexus revenue realized in FY2027 itself, driven mainly by two hyperscaler sites.
• CEO John Zillmer: it depends on scaling the sites on schedule
Analysis, not advice. I don't hold Aramark (NYSE: ARMK).
72
In August, Ashok Leyland's CEO said Q2 would be the peak of input-cost pressure and Q3 should soften. On Nov. 16 Shenu Agarwal said Q3 would also be a bad quarter for inflation, with steel and natural rubber already pushing up costs.
• Q2 EBITDA margin held at 10.1% on revenue up 39%
Analysis, not advice. I don't hold Ashok Leyland (NSE: ASHOKLEY).
132
In August, Rede D'Or (B3: RDOR3) said it had seen fewer M&A opportunities lately. On Nov. 13 its president, Paulo Moll, said the M&A team has opportunities and he hopes to be more active than in the last four years.
• Deal size and timing were not given
Analysis, not advice. I don't hold Rede D'Or (B3: RDOR3).
26
In August, Davivienda Group (BVC: PFDAVIGRP) called its integration on plan. On Nov. 13 the CEO said savings from shutting down DAVIbank's platform will take a few more months, probably Q2 2027.
• 2028-29 targets unchanged
• 2026 ROAE guide raised to 10.5-11.5%
Analysis, not advice. I don't hold Davivienda Group (BVC: PFDAVIGRP).
63
$DIS reports Nov 17. Last quarter it made three promises.
1. Parks and cruises: operating income growth at the high end of high single digits for fiscal 2026
2. Buybacks: at least $9B in fiscal 2026, up from about $7B
3. Disney+ and Hulu: a double-digit operating margin for fiscal 2026
I'll check each one after the call.
Analysis, not advice. I don't hold $DIS.
67
$CSCO moved its FY27 hyperscaler AI goal from $7.5B in August to $9B.
• $1.5B of the $2.5B raise to its full-year revenue guide is hyperscale: 60%
• About 8 points of the 19% growth guide come from hyperscale
• FY27 revenue guide: $74.8B-$75.8B, from $72.2B-$73.4B
Analysis, not advice. I don't hold $CSCO.
27
In August, Unipol (BIT: UNI) said converting its 4.9% BPER derivatives into shares would have an important capital impact. On Nov. 13 CEO Matteo Laterza said it will convert before the April general shareholder meeting.
• He said Unipol will choose the right moment to convert
Analysis, not advice. I don't hold Unipol (BIT: UNI).
22
$CBRS raised its 2026 revenue outlook for the second straight quarter.
Shares jumped about 18% after hours on Nov 12 (Nasdaq).
• Q3 core revenue: $230.9M, up 70%, vs a $214M-$216M guide
• 2026 core revenue outlook: $940M-$960M, up from $880M-$890M in August
• First positive core net income as a public company: $29.8M
The catch, per CEO Andrew Feldman: "Our delays right now are exclusively land, power, shell."
Analysis, not advice. I don't hold $CBRS.
115
In May, Richemont (SIX: CFR) said it had not decided whether to claim U.S. tariff refunds. On Nov. 13 it reported €229M of one-time tariff-related gains, and the CFO said no additional refunds are expected in H2.
• The gains added 1.9 points to gross margin
• Without them, it fell 0.7 points
Analysis, not advice. I don't hold Richemont (SIX: CFR).
29
Siemens (SIE.DE) laid out how the Healthineers spin-off will work.
• One Healthineers share for every two Siemens shares, on a 34.1% stake
• Shareholder votes in February; effective late spring, pending approvals
• Healthineers moves to discontinued operations from Q1 FY27
• Next: the spin-off report is due December 10
Analysis, not advice. I don't hold Siemens (SIE.DE).
1
47
This week I checked 15 promises CEOs made last quarter. They kept 12.
Rocket Lab: Neutron first launch, slipped
Nebius: ARR target, slipped
Take-Two: Q2 net bookings, missed
Cerebras: 2026 revenue outlook, beat
Analysis, not advice. I don't hold $CEG $HIMS $RKLB $TTD $TTWO $CRWV $ONON $SE $AMAT $CSCO $NBIS $CBRS, SoftBank (9984.T), Siemens Energy (ENR.DE) or Siemens (SIE.DE).
159
This week in earnings calls, in their own words:
Rocket Lab: “I think if I provide a date, clearly, I've been wrong.”
Cerebras: “Our delays right now are exclusively land, power, shell.”
On Holding: “This was a quarter in which much of our industry traded price for volume.”
Analysis, not advice. I don't hold $RKLB $CBRS $ONON.
55
Siemens (SIE.DE) laid out how the Healthineers spin-off will work.
• One Healthineers share for every two Siemens shares, on a 34.1% stake
• Shareholder votes in February; effective late spring, pending approvals
• Healthineers moves to discontinued operations from Q1 FY27
• Next: the spin-off report is due December 10
Analysis, not advice. I don't hold Siemens (SIE.DE).
46
$CSCO moved its FY27 hyperscaler AI goal from $7.5B in August to $9B.
• $1.5B of the $2.5B raise to its full-year revenue guide is hyperscale: 60%
• About 8 points of the 19% growth guide come from hyperscale
• FY27 revenue guide: $74.8B-$75.8B, from $72.2B-$73.4B
Analysis, not advice. I don't hold $CSCO.
35
$CRWV's new 10-Q says its rumor risk already happened.
Last quarter, negative publicity was written as an if. Now the filing says that in October 2026 its stock and some notes:
"declined significantly and market yields on certain of our notes increased substantially due in part to negative publicity and market rumors"
The rumors it names were about its debt and its ability to get financing.
Filed Nov 12.
Analysis, not advice. I don't hold $CRWV.
40




















